1
|
Johnson DJG, Jenkins ID, Huxley C, Coster MJ, Lum KY, White JM, Avery VM, Davis RA. Synthesis of New Triazolopyrazine Antimalarial Compounds. Molecules 2021; 26:molecules26092421. [PMID: 33919319 PMCID: PMC8122397 DOI: 10.3390/molecules26092421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 04/15/2021] [Accepted: 04/15/2021] [Indexed: 11/29/2022] Open
Abstract
A radical approach to late-stage functionalization using photoredox and Diversinate™ chemistry on the Open Source Malaria (OSM) triazolopyrazine scaffold (Series 4) resulted in the synthesis of 12 new analogues, which were characterized by NMR, UV, and MS data analysis. The structures of four triazolopyrazines were confirmed by X-ray crystal structure analysis. Several minor and unexpected side products were generated during these studies, including two resulting from a possible disproportionation reaction. All compounds were tested for their ability to inhibit the growth of the malaria parasite Plasmodium falciparum (3D7 and Dd2 strains) and for cytotoxicity against a human embryonic kidney (HEK293) cell line. Moderate antimalarial activity was observed for some of the compounds, with IC50 values ranging from 0.3 to >20 µM; none of the compounds displayed any toxicity against HEK293 at 80 µM.
Collapse
Affiliation(s)
- Daniel J. G. Johnson
- Griffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia; (D.J.G.J.); (I.D.J.); (C.H.); (M.J.C.); (K.Y.L.); (V.M.A.)
| | - Ian D. Jenkins
- Griffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia; (D.J.G.J.); (I.D.J.); (C.H.); (M.J.C.); (K.Y.L.); (V.M.A.)
| | - Cohan Huxley
- Griffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia; (D.J.G.J.); (I.D.J.); (C.H.); (M.J.C.); (K.Y.L.); (V.M.A.)
| | - Mark J. Coster
- Griffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia; (D.J.G.J.); (I.D.J.); (C.H.); (M.J.C.); (K.Y.L.); (V.M.A.)
| | - Kah Yean Lum
- Griffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia; (D.J.G.J.); (I.D.J.); (C.H.); (M.J.C.); (K.Y.L.); (V.M.A.)
- NatureBank, Griffith University, Brisbane, QLD 4111, Australia
| | - Jonathan M. White
- School of Chemistry and Bio21 Institute, The University of Melbourne, Melbourne, VIC 3010, Australia;
| | - Vicky M. Avery
- Griffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia; (D.J.G.J.); (I.D.J.); (C.H.); (M.J.C.); (K.Y.L.); (V.M.A.)
- Discovery Biology, Griffith University, Brisbane, QLD 4111, Australia
| | - Rohan A. Davis
- Griffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia; (D.J.G.J.); (I.D.J.); (C.H.); (M.J.C.); (K.Y.L.); (V.M.A.)
- NatureBank, Griffith University, Brisbane, QLD 4111, Australia
- Correspondence: ; Tel.: +61-7-3735-6043
| |
Collapse
|
2
|
Sammons MF, Kharade SV, Filipski KJ, Boehm M, Smith AC, Shavnya A, Fernando DP, Dowling MS, Carpino PA, Castle NA, Zellmer SG, Antonio BM, Gosset JR, Carlo A, Denton JS. Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors. ACS Med Chem Lett 2018; 9:125-130. [PMID: 29456800 DOI: 10.1021/acsmedchemlett.7b00481] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Accepted: 01/19/2018] [Indexed: 02/05/2023] Open
Abstract
Inhibitors of the renal outer medullary potassium channel (ROMK) show promise as novel mechanism diuretics, with potentially lower risk of diuretic-induced hypokalemia relative to current thiazide and loop diuretics. Here, we report the identification of a novel series of 3-sulfamoylbenzamide ROMK inhibitors. Starting from HTS hit 4, this series was optimized to provide ROMK inhibitors with good in vitro potencies and well-balanced ADME profiles. In contrast to previously reported small-molecule ROMK inhibitors, members of this series were demonstrated to be highly selective for inhibition of human over rat ROMK and to be insensitive to the N171D pore mutation that abolishes inhibitory activity of previously reported ROMK inhibitors.
Collapse
Affiliation(s)
- Matthew F. Sammons
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Sujay V. Kharade
- Department
of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
| | - Kevin J. Filipski
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Markus Boehm
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Aaron C. Smith
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Andre Shavnya
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Dilinie P. Fernando
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Matthew S. Dowling
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Philip A. Carpino
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Neil A. Castle
- Neusentis, Pfizer Worldwide Research & Development, Durham, North Carolina 27703, United States
| | - Shannon G. Zellmer
- Neusentis, Pfizer Worldwide Research & Development, Durham, North Carolina 27703, United States
| | - Brett M. Antonio
- Neusentis, Pfizer Worldwide Research & Development, Durham, North Carolina 27703, United States
| | - James R. Gosset
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Anthony Carlo
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jerod S. Denton
- Department
of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
| |
Collapse
|
3
|
The therapeutic potential of targeting the K ir1.1 (renal outer medullary K +) channel. Future Med Chem 2017; 9:1963-1977. [PMID: 29076349 DOI: 10.4155/fmc-2017-0083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Kir1.1 (renal outer medullary K+) channels are potassium channels expressed almost exclusively in the kidney and play a role in the body's electrolyte and water balance. Potassium efflux through Kir1.1 compliments the role of transporters and sodium channels that are the targets of known diuretics. Consequently, loss-of-function mutations in men and rodents are associated with salt wasting and low blood pressure. On this basis, Kir1.1 inhibitors may have value in the treatment of hypertension and heart failure. Efforts to develop small molecule Kir1.1 inhibitors produced MK-7145, which entered into clinical trials. The present manuscript describes the structure-activity relationships associated with this scaffold alongside other preclinical Kir1.1 blockers.
Collapse
|
4
|
Gallibois CM, Jawa NA, Noone DG. Hypertension in pediatric patients with chronic kidney disease: management challenges. Int J Nephrol Renovasc Dis 2017; 10:205-213. [PMID: 28794651 PMCID: PMC5538700 DOI: 10.2147/ijnrd.s100891] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
In contrast to adults where hypertension is a leading cause of chronic kidney disease, in pediatrics, hypertension is predominantly a sequela, however, an important one that, like in adults, is likely associated with a more rapid decline in kidney function or progression of chronic kidney disease to end stage. There is a significant issue with unrecognized, or masked, hypertension in childhood chronic kidney disease. Recent evidence and, therefore, guidelines now suggest targeting a blood pressure of <50th percentile for age, sex, and height in children with proteinuria and chronic kidney disease. This often cannot be achieved by monotherapy and additional agents need to be added. Blockade of the renin angiotensin aldosterone system represents the mainstay of therapy, although often limited by the side effect of hyperkalemia. The addition of a diuretic, at least in the earlier stages of chronic kidney disease, might help mitigate this problem.
Collapse
Affiliation(s)
- Claire M Gallibois
- Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
- Faculty of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Natasha A Jawa
- Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Damien G Noone
- Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
| |
Collapse
|
5
|
Abdel-Magid AF. Potential of Renal Outer Medullary Potassium (ROMK) Channel as Treatments for Hypertension and Heart Failure. ACS Med Chem Lett 2017; 8:9-10. [PMID: 28105264 DOI: 10.1021/acsmedchemlett.6b00457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2016] [Indexed: 11/30/2022] Open
|
7
|
Blass B. Inhibitors of Renal Outer Medullary Potassium Channel. ACS Med Chem Lett 2016; 7:447-8. [PMID: 27190590 DOI: 10.1021/acsmedchemlett.6b00131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2016] [Indexed: 11/28/2022] Open
Affiliation(s)
- Benjamin Blass
- Temple University School of Pharmacy , 3307 North Broad Street, Philadelphia, Pennsylvania 19140, United States
| |
Collapse
|